Search International and National Patent Collections

1. (WO2018200489) IL-8, IL-6, IL-1B AND TET2 AND DNMT3A IN ATHEROSCLEROSIS

Pub. No.:    WO/2018/200489    International Application No.:    PCT/US2018/029098
Publication Date: Fri Nov 02 00:59:59 CET 2018 International Filing Date: Wed Apr 25 01:59:59 CEST 2018
IPC: C12Q 1/6883
Applicants: THE BRIGHAM AND WOMEN’S HOSPITAL, INC.
THE GENERAL HOSPITAL CORP.
SIDDHARTHA, Jaiswal
KATHIRESAN, Sekar
EBERT, Benjamin
Inventors: SIDDHARTHA, Jaiswal
KATHIRESAN, Sekar
EBERT, Benjamin
Title: IL-8, IL-6, IL-1B AND TET2 AND DNMT3A IN ATHEROSCLEROSIS
Abstract:
The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.